SB-366791，25MG，S0441-25MG，Sigma

Application

SB-366791 has been used as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist:

• to infer the in vitro and in vivo pharmacology of (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide (AMG 9810)
• to study its effects on sodium hydrogen sulfide (NaHS) or capsaicin-induced contractile activity
• to study the inhibitory potency of phoneutria toxin (PnTx3-5) (native and recombinant) on various responses mediated by transient receptor potential cation channel subfamily V member 1 (TRPV1)

Biochem/physiol Actions

SB-366791 might exhibit analgesic properties on bone cancer-related pain behavior.
Vanilloid receptor-1 (TRPV1) antagonist.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.